

**Summary of Consolidated Financial Results [ IFRS ]  
for the First Three Months of the Fiscal Year Ending March 31, 2018**

August 4, 2017

Listed company name : Sysmex Corporation  
Code : 6869  
Listed stock exchanges : Tokyo Stock Exchange  
URL : <http://www.sysmex.co.jp>  
Company representative : Hisashi Ietsugu, Chairman and CEO  
Contact : Hiroshi Nagao, Executive Officer,  
Corporate Business Administration  
Phone : 078(265)-0500  
Scheduled date for filing of quarterly report : August 10, 2017  
Scheduled date for dividend payment : —  
Preparation of supplementary material for  
quarterly earnings : Yes  
Holding of earnings announcement : Yes

(Unit: Millions of Yen)

**1. Results for the First Three Months of the Fiscal Year Ending March 31, 2018**

(1) Operating results

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Three months ended Jun. 30, 2017	61,719	4.3%	12,432	(10.4)%	11,940	(3.0)%	8,126	(13.9)%
Three months ended Jun. 30, 2016	59,167	2.6%	13,877	7.7%	12,307	(4.6)%	9,439	18.2%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)		Diluted earnings per share (Yen)	
Three months ended Jun. 30, 2017	8,220	(13.0)%	11,453	—	39.48		39.39	
Three months ended Jun. 30, 2016	9,449	18.3%	667	(94.2)%	45.44		45.28	

Note: During the second quarter of the fiscal year ended March 31, 2017, Sysmex determined provisional accounting treatment for business combinations. Accordingly, figures for the first quarter of the fiscal year ended March 31, 2017, reflect content determined under provisional accounting treatment.

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets
As of Jun. 30, 2017	284,582	215,527	214,781	75.5%
As of Mar. 31, 2017	279,817	210,252	209,406	74.8%

**2. Dividend**

	Dividend per share				
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)
Year ended Mar. 31, 2017	—	28.00	—	30.00	58.00
Year ending Mar. 31, 2018	—				
Year ending Mar. 31, 2018 (Forecast)		30.00	—	30.00	60.00

Note: Revision of dividends forecast for this period: No

### 3. Financial Forecast for the Year Ending March 31, 2018

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
		%		%		%		%	
Six months ending Sep. 30, 2017	128,000	7.7%	27,500	1.7%	27,000	7.8%	19,500	(17.0)%	93.66
Year ending Mar. 31, 2018	275,000	10.0%	57,000	10.2%	56,000	14.4%	41,000	0.9%	196.92

Note: Revision of business forecast for this period: No

### 4. Other Information

(1) Changes in significant consolidated subsidiaries (which resulted in changes in scope of consolidation):  
No

(2) Changes in accounting policies and accounting estimates

1) Changes in accounting policies required by IFRS: No

2) Other changes in accounting policies: No

3) Changes in accounting estimates: No

(3) Number of outstanding stock (common stock)

1) Number of outstanding stock at the end of each fiscal period (including treasury stock):  
208,658,432 shares as of Jun. 30, 2017; 208,631,032 shares as of Mar. 31, 2017

2) Number of treasury stock at the end of each fiscal period:  
444,672 shares as of Jun. 30, 2017; 444,556 shares as of Mar. 31, 2017

3) Average number of outstanding stock for each period (cumulative):  
208,202,753 shares for the three months ended Jun. 30, 2017  
207,971,768 shares for the three months ended Jun. 30, 2016

Note: Quarterly summaries of financial results are excluded from quarterly reviews.

\* Explanation regarding the appropriate use of financial forecast and other information

1. Basic earnings per share have been revised from the figures indicated in the consolidated financial forecast announced on May 10, 2017, in accordance with changes in the number of shares of outstanding stock and treasury stock. No other figures in the financial forecast have been revised.

2. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to “3) Consolidated financial forecast” within “1. Financial Performance” on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.

3. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Friday, August 4, 2017.

## Content of Supplementary Materials

1. Financial performance	2
1) Performance analysis	2
2) Financial conditions analysis	5
3) Consolidated financial forecast	5
2. Condensed quarterly consolidated financial statements and notes	6
1) Condensed quarterly consolidated statement of financial position	6
2) Condensed quarterly consolidated statement of income	8
3) Condensed quarterly consolidated statement of other comprehensive income	9
4) Condensed quarterly consolidated statement of changes in equity	10
5) Condensed quarterly consolidated statement of cash flows	11
6) Notes to the condensed quarterly consolidated financial statements	12
1. Notes related to the going concern assumption	12
2. Segment information	12

## 1. Financial performance

### 1) Performance analysis

Future-related information contained in the text below is based on the judgement of the Sysmex Group (Sysmex Corporation and its affiliated companies) as of the end of the fiscal period under review.

During the first three months of the fiscal year ending March 31, 2018, the Japanese economy continued to recover, buoyed by rebounds in personal consumption and capital investment. Overall, the overseas economy also continued its modest recovery.

On the healthcare front, the Japanese government is including the medical and healthcare industry in its growth strategies, which is expected to continue invigorating healthcare-related industries going forward. In the United States, the Affordable Care Act that was introduced to decrease the number of people without medical insurance is being reviewed. In China, the country is also introducing policies to curtail medical expenses, but overseas the foundations of healthcare-related demand remain solid.

Under these conditions, Sysmex acquired the shares of Oxford Gene Technology IP Limited (“OGT”) and converted the company to a subsidiary. In the cytogenetics market, we plan to reinforce our technology base for genomic medicine by fusing Sysmex’s flow FISH<sup>1</sup> and other automation technologies with OGT’s capabilities in the development of high-quality reagents.

To reinforce its R&D related to information analysis technology, centered on bioinformatics<sup>2</sup>, Sysmex established a new R&D facility, the Skyfront Research Campus, within the Life Innovation Center, located within the Kawasaki INnovation Gateway at SKYFRONT<sup>3</sup>, in the Tonomachi area of Kawasaki, Kanagawa Prefecture. This area is home to a cluster of leading-edge life science companies and research institutions. In establishing an R&D facility there, Sysmex aims to facilitate collaboration with R&D institutions, universities and companies in the Kanto area.

The RIKEN GENESIS Innovation Genome Center of RIKEN GENESIS Co., Ltd., a Sysmex subsidiary, is located in the same center. We will employ next-generation sequencers<sup>4</sup> and cutting-edge gene analyzers for liquid biopsy<sup>5</sup>, to provide gene analysis service and to perform clinical sequence testing<sup>6</sup> to quality levels based on international quality standards, thereby contributing to the promotion of genomic medicine.

#### 1 Flow FISH:

Whereas FISH testing requires evaluation of slides under a microscope, flow FISH testing uses an imaging flow cytometer to capture images, enabling automated analysis. FISH testing uses fluorescent material binding only specific genes to detect target genes within a chromosome.

#### 2 Bioinformatics:

Information technology that analyzes genetic and protein information to explain Biological function and phenotype; in particular, signifying the technology for analyzing relationships between genetic information and disease.

#### 3 Kawasaki INnovation Gateway at SKYFRONT:

An open innovation hub located within the Life Innovation in Keihin Coastal Areas International Strategy Comprehensive Special Zone, where companies involved in the life sciences gather. Based on national government growth strategy, the hub is eligible for support, including the easing of regulations, with a view to establishing innovative business models.

#### 4 Next-generation sequencer (NGS):

An analyzer for reading the huge volumes of genetic information contained in DNA bases and sequences.

#### 5 Liquid biopsy:

Detection of cancer or other diseases by testing bodily fluids such as blood. This type of testing is less invasive than conventional physical biopsies.

#### 6 Clinical sequence testing:

The type of testing which analyzes genetic information of patients with a high degree of precision by using the next-generation sequencer with the purpose of diagnosis and treatment methods selection.

Net sales by destination

	Three months ended June 30, 2016		Three months ended June 30, 2017		YoY (Previous period = 100)
	Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan	9,201	15.6	9,394	15.2	102.1
Americas	13,361	22.6	14,334	23.2	107.3
EMEA	17,267	29.2	16,737	27.1	96.9
China	14,461	24.4	16,174	26.2	111.8
Asia Pacific	4,875	8.2	5,078	8.3	104.2
Overseas subtotal	49,965	84.4	52,325	84.8	104.7
Total	59,167	100.0	61,719	100.0	104.3

In Japan, reagent sales increased, centered on the hematology and hemostasis fields. As a result, sales in Japan rose 2.1% year on year, to ¥9,394 million.

In overseas markets, reagent sales expanded thanks to a growing installed instrument base in the hematology, urinalysis and immunochemistry fields. Consequently, the Sysmex Group's overseas sales increased 4.7% year on year, to ¥52,325 million. The overseas sales ratio rose 0.4 percentage point, to 84.8%.

As a result, during the first three months of the year the Group recorded consolidated net sales of ¥61,719 million, up 4.3% year on year. Operating profit declined 10.4%, to ¥12,432 million, and profit before tax fell 3.0%, to ¥11,940 million. Profit attributable to owners of the parent declined 13.0%, to ¥8,220 million.

## Performance by segment

### (1) Japan

Sales of reagents in the hematology and hemostasis fields increased in Japan, but export sales decreased. Sales in this segment consequently fell 2.7% year on year, to ¥9,682 million.

On the profit front, despite the positive impact of sales growth in Japan, cost of sales increased and SG&A expenses rose. These and other factors led to a 5.7% fall in segment profit (operating profit), to ¥9,431 million.

### (2) Americas

In Central and South America, sales fell on a local currency basis, reflecting the acquisition of government projects in Mexico in the corresponding period of the previous fiscal year. In the United States, favorable instrument sales led to higher sales, primarily in the hematology field. Overall, sales in the Americas grew 12.2% year on year, to ¥13,999 million.

Segment profit (operating profit) surged 188.1%, to ¥1,657 million, thanks to higher sales and such factors as lower payments of Group trademark royalties.

### (3) EMEA

Sales of instruments declined, mainly in the hematology and hemostasis fields, causing sales to drop 3.6% year on year, to ¥16,803 million.

In addition to the impact of lower sales, performance was affected by higher SG&A expenses, as we worked to reinforce our sales structure. As a result, segment profit (operating profit) decreased 13.7% year on year, to ¥1,314 million.

### (4) China

Reagent sales grew in the hematology and immunochemistry fields, pushing up sales 11.8% year on year, to ¥16,166 million.

In addition to the effect of higher sales, the cost of sales ratio improved due to a revision in intragroup transaction prices. Segment profit (operating profit) expanded 134.1%, to ¥1,849 million.

### (5) Asia Pacific

Sales of instruments decreased, reflecting sales of instruments to large-scale commercial labs in Australia in the corresponding period of the previous fiscal year. However, sales of reagents grew, owing to an increase in the installed instrument base in the hematology and hemostasis fields, pushing up sales 4.6% year on year, to ¥5,068 million.

Although SG&A expenses increased, segment profit (operating profit) grew 23.3% year on year, to ¥452 million, due to the effect of higher sales, which pushed up gross profit.

## 2) Financial conditions analysis

### (1) Assets, liabilities and equity

As of June 30, 2017, total assets amounted to ¥284,582 million, up ¥4,765 million from March 31, 2017. As principal factors, despite a ¥11,895 million decrease in cash and cash equivalents, goodwill increased ¥6,869 million, inventories rose ¥5,861 million, property, plant and equipment grew ¥2,046 million, and intangible assets expanded ¥1,603 million.

Meanwhile, total liabilities as of June 30, 2017, were ¥69,054 million, down ¥509 million from their level on March 31, 2017. Principal factors included decreases of ¥3,074 million in accrued bonuses and ¥1,268 million in trade and other payables, despite increases of ¥1,644 million in income taxes payable and ¥1,595 million in other short-term financial liabilities.

Total equity came to ¥215,527 million, up ¥5,274 million from March 31, 2017. Among principal reasons, retained earnings rose ¥1,975 million, and other components of equity increased ¥3,326 million. Equity attributable to owners of the parent to total assets as of June 30, 2017, was 75.5%, up 0.7 percentage point from the 74.8% recorded as of March 31, 2017.

### (2) Cash flows

As of June 30, 2017, cash and cash equivalents amounted to ¥46,048 million, down ¥11,895 million from March 31, 2017.

Cash flows from various activities during the first three months of the fiscal year are described in more detail below.

#### (Cash flows from operating activities)

Net cash provided by operating activities was ¥9,838 million, up ¥9,135 million from the first three months of the preceding fiscal year. As principal factors, profit before tax provided ¥11,940 million (¥366 million less than in the corresponding period of the preceding year), a decrease in trade receivables provided ¥3,894 million (up ¥2,408 million). An increase in inventories used ¥3,463 million (up ¥1,758 million), a decrease in advances received used ¥609 million (down ¥3,851 million), and income taxes paid used ¥3,072 million (down ¥4,022 million).

#### (Cash flows from investing activities)

Net cash used in investing activities was ¥16,079 million (up ¥9,585 million). Among major factors, purchases of property, plant and equipment used ¥3,119 million (down ¥75 million from the corresponding period of the previous fiscal year), purchases of intangible assets used ¥1,640 million (up ¥339 million), purchases of investments in equity instruments used ¥1,706 million (up ¥1,076 million) and acquisitions of subsidiaries or other businesses used ¥9,469 million (up ¥8,016 million).

#### (Cash flows from financing activities)

Net cash used in financing activities was ¥6,220 million (up ¥745 million). This was mainly due to dividends paid of ¥6,245 million (up ¥424 million).

## 3) Consolidated financial forecast

The Company maintains its consolidated financial forecasts, as announced on May 10, 2017.

These forecasts are based on information available as of the date of this release. Actual results may differ materially from these forecast due to unforeseen factors and future events.

## 2. Condensed quarterly consolidated financial statements and notes

### 1) Condensed quarterly consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2017	As of June 30, 2017
Assets		
Current assets		
Cash and cash equivalents	57,944	46,048
Trade and other receivables	63,084	60,811
Inventories	36,998	42,860
Other short-term financial assets	528	465
Income taxes receivables	457	428
Other current assets	7,303	6,570
Total current assets	166,318	157,185
Non-current assets		
Property, plant and equipment	60,144	62,191
Goodwill	8,308	15,178
Intangible assets	21,228	22,832
Investments accounted for using the equity method	552	1,624
Trade and other receivables	8,813	9,084
Other long-term financial assets	6,107	6,976
Asset for retirement benefits	666	661
Other non-current assets	2,095	2,182
Deferred tax assets	5,581	6,664
Total non-current assets	113,499	127,396
Total assets	279,817	284,582

(Unit: Millions of yen)

	As of March 31, 2017	As of June 30, 2017
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	24,376	23,107
Other short-term financial liabilities	956	2,551
Income taxes payable	2,915	4,559
Provisions	610	581
Advances received	6,418	5,907
Accrued expenses	8,330	8,166
Accrued bonuses	6,636	3,561
Other current liabilities	9,708	10,817
Total current liabilities	59,952	59,253
Non-current liabilities		
Long-term financial liabilities	549	509
Liability for retirement benefits	654	683
Provisions	2,318	2,293
Other non-current liabilities	3,527	3,377
Deferred tax liabilities	2,562	2,937
Total non-current liabilities	9,612	9,801
Total liabilities	69,564	69,054
Equity		
Equity attributable to owners of the parent		
Capital stock	11,611	11,666
Capital surplus	17,303	17,322
Retained earnings	188,506	190,481
Treasury stock	(289)	(289)
Other components of equity	(7,725)	(4,398)
Total equity attributable to owners of the parent	209,406	214,781
Non-controlling interests	845	745
Total equity	210,252	215,527
Total liabilities and equity	279,817	284,582

## 2) Condensed quarterly consolidated statement of income

(Unit: Millions of yen)

	Three months ended June 30, 2016	Three months ended June 30, 2017
Net sales	59,167	61,719
Cost of sales	24,752	26,848
Gross profit	34,414	34,870
Selling, general and administrative expenses	17,236	18,895
Research and development expenses	3,831	3,658
Other operating income	606	141
Other operating expenses	75	25
Operating profit	13,877	12,432
Financial income	210	71
Financial expenses	28	24
Share of profit (loss) of associates accounted for using the equity method	(155)	(128)
Foreign exchange gain (loss)	(1,597)	(409)
Profit before tax	12,307	11,940
Income taxes expenses	2,868	3,813
Profit	9,439	8,126
Profit attributable to		
Owners of the parent	9,449	8,220
Non-controlling interests	(10)	(93)
Profit	9,439	8,126
		(Unit: Yen)
Earnings per share		
Basic	45.44	39.48
Diluted	45.28	39.39

## 3) Condensed quarterly consolidated statement of other comprehensive income

(Unit: Millions of yen)

	Three months ended June 30, 2016	Three months ended June 30, 2017
Profit	9,439	8,126
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	(205)	198
Total	(205)	198
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	(8,558)	3,128
Share of other comprehensive income of investments accounted for using the equity method	(7)	(0)
Total	(8,565)	3,128
Total other comprehensive income	(8,771)	3,326
Comprehensive income	667	11,453
Comprehensive income attributable to		
Owners of the parent	677	11,547
Non-controlling interests	(10)	(93)
Comprehensive income	667	11,453

4) Condensed quarterly consolidated statement of changes in equity  
Three months ended June 30, 2016

(Unit: Millions of yen)

	Equity attributable to owners of the parent					Total	Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity			
As of April 1, 2016	11,016	16,969	159,375	(285)	(4,275)	182,800	0	182,801
Profit			9,449			9,449	(10)	9,439
Other comprehensive income					(8,771)	(8,771)	(0)	(8,771)
Comprehensive income	—	—	9,449	—	(8,771)	677	(10)	667
Exercise of warrants	266	149				415		415
Cash dividends			(5,820)			(5,820)		(5,820)
Purchase of treasury stock				(0)		(0)		(0)
Changes from business combination						—	1,028	1,028
Equity transactions with non-controlling interests		—				—	—	—
Total transactions with the owners	266	149	(5,820)	(0)	—	(5,406)	1,028	(4,377)
As of June 30, 2016	11,283	17,118	163,004	(286)	(13,046)	178,072	1,019	179,091

Three months ended June 30, 2017

(Unit: Millions of yen)

	Equity attributable to owners of the parent					Total	Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity			
As of April 1, 2017	11,611	17,303	188,506	(289)	(7,725)	209,406	845	210,252
Profit			8,220			8,220	(93)	8,126
Other comprehensive income					3,326	3,326	0	3,326
Comprehensive income	—	—	8,220	—	3,326	11,547	(93)	11,453
Exercise of warrants	54	30				85		85
Cash dividends			(6,245)			(6,245)		(6,245)
Purchase of treasury stock				(0)		(0)		(0)
Changes from business combination						—	—	—
Equity transactions with non-controlling interests		(11)				(11)	(6)	(18)
Total transactions with the owners	54	19	(6,245)	(0)	—	(6,172)	(6)	(6,179)
As of June 30, 2017	11,666	17,322	190,481	(289)	(4,398)	214,781	745	215,527

## 5) Condensed quarterly consolidated statement of cash flows

(Unit: Millions of yen)

	Three months ended June 30, 2016	Three months ended June 30, 2017
Cash flows from operating activities		
Profit before tax	12,307	11,940
Depreciation and amortization	3,280	3,481
Decrease (increase) in trade receivable	1,485	3,894
Decrease (increase) in inventories	(1,704)	(3,463)
Increase (decrease) in trade payable	(1,683)	688
Increase (decrease) in consumption taxes receivable and payable	2,445	1,659
Increase (decrease) in advances received	(4,461)	(609)
Increase (decrease) in accrued bonuses	(3,435)	(3,198)
Other	(609)	(1,534)
Subtotal	7,624	12,857
Interest and dividend received	197	68
Interest paid	(24)	(14)
Income taxes paid	(7,094)	(3,072)
Net cash provided by (used in) operating activities	702	9,838
Cash flows from investing activities		
Purchases of property, plant and equipment	(3,194)	(3,119)
Purchases of intangible assets	(1,300)	(1,640)
Purchases of investments in equity instruments	(629)	(1,706)
Acquisitions of subsidiaries or other businesses	(1,453)	(9,469)
Other	84	(144)
Net cash provided by (used in) investing activities	(6,493)	(16,079)
Cash flows from financing activities		
Dividends paid	(5,820)	(6,245)
Other	345	24
Net cash provided by (used in) financing activities	(5,475)	(6,220)
Effects of exchange rate changes on cash and cash equivalents	(2,617)	566
Net increase (decrease) in cash and cash equivalents	(13,883)	(11,895)
Cash and cash equivalents at the beginning of the term	56,481	57,944
Cash and cash equivalents at the end of the term	42,598	46,048

6) Notes to the condensed quarterly consolidated financial statements

1. Notes related to the going concern assumption

Not applicable

2. Segment information

1) Overview of reportable segments

The Group's reportable segments are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan by the Company, and in the Americas, EMEA, China and the Asia Pacific by regional headquarters established in those regions. These companies formulate overarching strategies tailored to regional characteristics and conduct business activities accordingly. Regional headquarters and other domestic and overseas subsidiaries are independent management units that handle production and sales for each region.

Accordingly, the Group has five reportable segments comprising geographical segments based on manufacturing and sales systems. These are "Japan," the "Americas," "EMEA," "China," and the "Asia Pacific."

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows:

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group's accounting policies indicated in the consolidated financial statements for the previous fiscal year.

Three months ended June 30, 2016

(Unit: Millions of yen)

	Reportable segment						Reconciliations	Consolidated
	Japan	Americas	EMEA	China	Asia Pacific	Total		
Sales								
Sales to external customers	9,949	12,477	17,436	14,458	4,845	59,167	—	59,167
Intersegment sales	23,332	86	576	1	8	24,005	(24,005)	—
Total	33,282	12,564	18,012	14,459	4,853	83,172	(24,005)	59,167
Segment profit	10,003	575	1,523	790	366	13,259	618	13,877
Financial income	—	—	—	—	—	—	—	210
Financial expenses	—	—	—	—	—	—	—	28
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(155)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(1,597)
Profit before tax	—	—	—	—	—	—	—	12,307
Income taxes expenses	—	—	—	—	—	—	—	2,868
Profit	—	—	—	—	—	—	—	9,439

Notes:

1. Segment profit reconciliations of ¥618 million include ¥4 million for the elimination of intersegment transfers, ¥654 million for the adjustment of inventories and negative ¥41 million for the adjustment of non-current assets.
2. Segment profit is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.

Three months ended June 30, 2017

(Unit: Millions of yen)

	Reportable segment						Reconcilia tions	Consolidated
	Japan	Americas	EMEA	China	Asia Pacific	Total		
Sales								
Sales to external customers	9,682	13,999	16,803	16,166	5,068	61,719	—	61,719
Intersegme nt sales	25,088	91	593	6	1	25,781	(25,781)	—
Total	34,770	14,091	17,396	16,172	5,069	87,500	(25,781)	61,719
Segment profit	9,431	1,657	1,314	1,849	452	14,705	(2,273)	12,432
Financial income	—	—	—	—	—	—	—	71
Financial expenses	—	—	—	—	—	—	—	24
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(128)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(409)
Profit before tax	—	—	—	—	—	—	—	11,940
Income taxes expenses	—	—	—	—	—	—	—	3,813
Profit	—	—	—	—	—	—	—	8,126

Notes:

1. Segment profit reconciliations of negative ¥2,273 million include negative ¥2 million for the elimination of intersegment transfers, negative ¥2,369 million for the adjustment of inventories and ¥100 million for the adjustment of non-current assets.
2. Segment profit is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.